ArticleFolia microbiologica2026
Akkermansia muciniphila WW001 protects against DSS-induced colitis by restoring intestinal barrier integrity and modulating inflammatory responses.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a chronic, relapsing disorder intimately linked to impaired intestinal barrier function. Akkermansia muciniphila, a beneficial gut bacterium, has been shown to enhance intestinal barrier function. This study aimed to characterize a newly identified strain, A. muciniphila WW001, and evaluate its protective effects on intestinal barrier integrity in IBD models. Lipopolysaccharide (LPS)-induced Caco-2/HT29-MTX cell model and dextran sulfate sodium (DSS)-induced mouse model were employed to assess its protective effects on intestinal barrier function. Whole-genome sequencing, comparative genomic analysis, and molecular docking were performed to explore the unique genetic characteristics of WW001. In line with these genomic features, WW001 significantly strengthened intestinal barrier function and displayed distinct functional characteristics compared with A. muciniphila ATCC 835, as evidenced by elevated transepithelial electrical resistance (TEER), reduced paracellular permeability, upregulation of tight junction proteins, suppression of pro-inflammatory cytokines, and elevation of anti-inflammatory cytokine levels. Furthermore, WW001 alleviated colitis symptoms and promoted goblet cell proliferation, which were associated with its distinct genomic features and increased short-chain fatty acid (SCFA) concentrations. The enriched glycoside hydrolase repertoire may indicate an enhanced capacity for mucin-derived glycan utilization; however, the causal relationships among these genomic features, mucin utilization, SCFA changes, and barrier protection remain to be established. These findings demonstrate that A. muciniphila WW001 enhances intestinal barrier function and exerts anti-inflammatory effects, while the associated metabolic changes may contribute to its beneficial effects, supporting its potential application as a probiotic candidate for IBD intervention.
Indexed as
Identifiers
42814370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.